The Straehla laboratory was established in 2022. Our research is focused at the intersection of nanotechnology and cancer biology with the ultimate goal of bringing nanomedicine into the clinic for cancer patients.
Two particular areas of focus are identifying nanoparticle-specific biomarkers and tackling challenging biologic barriers. We have a team science approach and love to collaborate with researchers from other disciplines. Please contact us if you are interested in finding out more!
Research in the Straehla Lab is supported by the Charles W. (1955) and Jennifer C. Johnson Cancer Research Fund, the MIT/DF/HCC Bridge Project, the Koch Institute Frontier Research Program, Rally Foundation for Childhood Cancer Research, Cannonball Kids' Cancer, the DIPG All-In Initiative, the American Association for Cancer Research (AACR) - Day One Biopharma Pediatric Cancer Research Fellowship, and the Burroughs Wellcome Fund.
We gratefully acknowledge past support from the Helen Gurley Brown Foundation, the Office of Faculty Development at Dana-Farber Cancer Institute, and the Department of Defense Congressionally Directed Medical Research Program Horizon Award.